Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.

BEACON and Open-Label Extension Study Design and Data Summary: ...

NMRA-861 has demonstrated a potentially best-in-class pharmacological profile and robust activity in preclinical efficacy models. NMRA-861 was safe and well-tolerated in pre-clinical toxicology ...

The clinical trial support services market is experiencing significant growth, driven by the increasing incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases. This rise ...

A systematic review of almost 50 randomized clinical trials brings some clarity to concerns about antidepressant withdrawal ...

In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"),the six-month radiographic progres ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Researchers have provided robust scientific evidence that ailments like depression, high blood pressure, diabetes mellitus, ...

Participants in the trial will undergo all three screening methods like mammography, ultrasound and the AI-based scan to ...

American children’s health has declined profoundly over the past few decades, a new study shows, and the issues are so ...

The project aims to understand the impact of existing therapies as forms of intervention on hospital outcomes, as well as one-year clinical outcomes, and to use appropriate measures to prevent them.

An FDA-funded clinical trial found even modest CBD use triggered elevated liver enzymes in some healthy adults, raising safety concerns.